NEW DELHI, April 20, 2015 /PRNewswire/ --
- Development of a Novel Taxane and a PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - To be Presented on Tuesday, Apr 21, 8:00 AM EST
- Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody and Camptothecin as Cytotoxic Payload - Presented on Sunday, Apr 19, 1:00 PM EST
Invictus Oncology Private Limited, a leader in supramolecular therapeutic program, today announced that the company’s novel computational platform technology (VOLVOX) for designing anti-cancer supramolecular therapeutics, and the CORDLink technology platform for designing Antibody Drug Conjugates (ADCs) will be presented at the American Association for Cancer Research (AACR) annual meeting being held in Philadelphia, PA, April 18-22.
Help employers find you! Check out all the jobs and post your resume.
